FindTrial
Sign In

OC000459

DRUG9 trials

Sponsors

Oxagen Ltd, Atopix Therapeutics, Ltd., Chiesi Farmaceutici S.p.A.

Conditions

Allergic RhinitisAsthmaAtopic DermatitisBronchial AsthmaEosinophilic EsophagitisHealthy VolunteersSevere Eosinophilic Asthma

Phase 1

Study to Evaluate the Potential for Interaction Between OC000459 and CYP 450 3A4
CompletedNCT01056575
Oxagen LtdHealthy Volunteers
Start: 2010-02-28End: 2010-05-31Target: 20Updated: 2010-09-02
Evaluation of Metabolic Profile of OC000459
CompletedNCT02341521
Atopix Therapeutics, Ltd.Asthma
Start: 2015-03-31End: 2015-05-31Updated: 2015-05-25

Phase 2

OC000459 Dose Finding Study in Hay Fever Sufferers.
CompletedNCT00697281
Oxagen LtdAllergic Rhinitis
Start: 2008-05-31End: 2008-09-30Target: 120Updated: 2009-02-24
Proof of Concept Study of OC000459 in Eosinophilic Esophagitis
CompletedNCT01056783
Oxagen LtdEosinophilic Esophagitis
Start: 2010-08-31End: 2011-06-30Updated: 2012-01-05
OC000459 Bronchial Allergen Challenge
CompletedNCT01056692
Oxagen LtdBronchial Asthma
Start: 2006-02-28Updated: 2010-01-26
Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects
CompletedNCT01057927
Oxagen LtdAsthma
Start: 2007-01-31End: 2007-11-30Updated: 2010-01-28
A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis
CompletedNCT01448902
Oxagen LtdAllergic Rhinitis
Start: 2007-03-31End: 2007-05-31Updated: 2011-10-07
Effect of OC000459 on Moderate to Severe Atopic Dermatitis
CompletedNCT02002208
Atopix Therapeutics, Ltd.Atopic Dermatitis
Start: 2013-10-31End: 2016-02-29Updated: 2018-03-26
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
CompletedNCT02560610
Chiesi Farmaceutici S.p.A.Severe Eosinophilic Asthma
Start: 2016-09-30End: 2018-08-02Updated: 2019-08-29

Related Papers

The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial.
2012-10-0175 citations
A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma.
2011-07-15163 citations